Cellular Origins
Cell therapy manufacturing automation, Cambridge
Robotic automation platforms for scalable cell and gene therapy manufacturing. It raised €34.2m in its Series A in December 2025. It has 8 roles open, 8 of them in the UK.
Backed by BGF, Highland Europe, Johnson & Johnson Innovation (JJDC) and NYBC Ventures.
Not found on the Home Office register of licensed visa sponsors.
- 14 daystypical age of an open role
- 1roles open for more than 60 days
- 9roles taken down since we started tracking
- 0%of roles list a salary
Open roles
8 live todayOpen roles over time
Hiring momentum
Roles per weekAdded (by posting date)Closed (removed from the board)In the news (hover for headline)
Open roles by function
Open roles by team
As the company labels themIn the news
All 20 stories- OtherBusiness Weekly, 8 days agoCellular Origins revolutionises CGT manufacturing with mobile robots
- Partnerships & dealsCleanroom Technology, 1 Oct 2026Cellular Origins VP on Fresenius Kabi collaboration
- OtherBioengineer.org, 7 Sept 2026Multiancestry GWAS and multiomics reveal cellular origins of multiple sclerosis genetics
- OtherANI News, 27 Jul 2026Phylogenomics Unlocks Sleep's Deepest Secret: Conserved Enzyme Network Reveals the Cellular Origins of Sleep
- ExpansionNews-Medical, 9 Jul 2026Autolomous and Cellular Origins expand platform integration to deliver end-to-end cell therapy manufacturing orchestration
- Partnerships & dealscontractpharma.com, 5 May 2026Cellular Origins, Immatics Partner for Automated Cell Therapy Manufacturing